New scanner at Addenbrooke's Hospital

In collaboration with the Press Association

A new scanning department has opened today (December 12th) at Addenbrooke's Hospital in Cambridge which will use PET/CT technology to improve the diagnosis and management of a range of illnesses, including cancer.

The department is the first PET-CT scanning department in East Anglia and one of only a handful throughout the UK.

The scanner uses a combination of Positron Emission Tomography (PET) and Computed Tomography (CT), providing three-dimensional images inside the patient's body.

Addenbrooke's new department will cater for patients from a range of specialities, including oncology, cardiology, neurology, gastroenterology, metabolic science and infectious diseases.

Professor David Lomas, from the hospital's Department of Radiology, revealed: "We can use PET/CT to improve our management of a wide range of illnesses.

"For example, in patients with certain types of cancer we can find small tumours deep inside the body that may not be easily detected using other imaging techniques. That can help us to tailor treatment to the individual patient at the time of diagnosis - and we can use further PET/CT studies to show how well it is working or if a tumour has recurred."

Professor Lomas noted that Addenbrooke's already provides a range of sophisticated diagnostic and therapeutic imaging techniques and said that the arrival of the new scanner is "excellent news" for patients.

The department was officially opened today at 12:30 GMT by Professor Patrick Sissons, Cambridge's Regius Professor of Physics.

It has been possible thanks to collaboration between Addenbrooke's, the Cambridge Biomedical Research Centre, Merck Sharp & Dohme (MSD), Cancer Research UK and the University of Cambridge.

Dr David Tuveson, from Cancer Research UK's Cambridge Research Institute, commented: "It is a testament to the world-class research taking place in Cambridge that MSD has chosen to work with us at the Addenbrooke's site.

"This equipment will enable us to remain at the forefront of research efforts on some of the hardest-to-treat cancers. We are extremely grateful to the company for their support."

Please help us improve our news stories by taking our short survey